<?xml version="1.0" encoding="UTF-8"?>
<p>The new regulation sets specific rules on the authorization and supervision of advanced therapy medicinal products and on pharmacovigilance in relation to them. The responsible central body for the licensing of the ATMPs is the EMA and the local competent bodies of the national drug organizations of the member states. At the same time, the Committee for Advanced Therapies (CAT) was established, the main role of which is to advise on the classification of a product [
 <xref rid="R06" ref-type="bibr">6</xref>].
</p>
